We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Golden Biotechnology said its drug candidate antroquinonol will enter Phase II trials in the US for treatment of severely ill COVID-19, pending authorisation by the authorities, in the third quarter, as reported Taipei Times.
In one of the first such confirmed cases, an Arkansas toddler who suffered severe brain injury after nearly drowning has had that brain damage reversed, using a new treatment.